Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.
Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – Deal potentially worth $200+ millionincreases Roche's investment in Freenome with $75 million equity instrument and R&D support through innovative applications and technology collaboration – Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration […]